

24 September 2010

**AquaBounty Technologies, Inc.**  
**(“AquaBounty” or “the Company”)**

**VMAC Meeting Concludes for AquaBounty’s AquaAdvantage® Salmon**

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces further progress on its pending New Animal Drug Application for AquaAdvantage® Salmon from the U.S. Food and Drug Administration (FDA).

Further to the announcements of 25 August and 6 September 2010, the Company confirms that the meeting of the Veterinary Medicine Advisory Committee (Committee or VMAC) held 19-20 September 2010 regarding AquaBounty’s pending application for its AquaAdvantage® Salmon has concluded and the Committee has made its comments to the FDA. The FDA will now consider the Committee’s input, along with comments from the general public.

The VMAC meeting was followed by a public hearing on 21 September 2010 on the labeling of food made from AquaAdvantage® Salmon. The FDA concluded that, if the agency approves the product, a decision will be made on labeling requirements. There is now a 60 day open period for public comment on this topic.

Dr. Ronald Stotish, President and CEO of AquaBounty, commented: “We have completed two more steps in the approval process for our AquaAdvantage® Salmon. The meetings have demonstrated how the application of our technology will enable the safe and sustainable production of a high quality fish that is no different in composition from other farmed Atlantic salmon. We now await the completion of the deliberative process and the formal decision of the FDA.”

**For further information, please contact:**

<b>AquaBounty Technologies</b> David Frank, Chief Financial Officer	+1 781 899 7755
<b>Nomura Code Securities</b> Richard Potts, Giles Balleny	+44 (0)20 7776 1200
<b>Corfin Public Relations</b> Harry Chathli, Claire Norbury	+44 (0)20 7596 2860